Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN SP versus DERMATOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN SP versus DERMATOP.
CORDRAN SP vs DERMATOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
Prednicarbate is a corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
Apply a thin layer to affected skin areas twice daily (morning and evening) for up to 4 weeks. Do not use more than 50 g per week.
None Documented
None Documented
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
Terminal elimination half-life: approximately 100 hours (range 68-120 hours) following topical administration; prolonged accumulation with chronic use due to high lipophilicity and slow release from skin depot.
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Primarily hepatic metabolism with inactive metabolites; <10% excreted renally as unchanged drug; minimal biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid